ST. PAUL, Minn., June 26, 2017 /PRNewswire/ -- EnteroMedics
Inc. (NASDAQ:ETRM), the developer of medical devices to treat
obesity, metabolic diseases and other gastrointestinal disorders,
today announced that the Company will join the Russell
Microcap® Index effective after the U.S. market opens
today.
Membership in the Russell Microcap Index, which remains in place
for one year, means automatic inclusion in the appropriate growth
and value style indexes. FTSE Russell determines membership for its
Russell indexes primarily by objective, market-capitalization
rankings and style attributes.
"EnteroMedics is very pleased to be added to such a widely
referenced index," said Dan Gladney,
EnteroMedics President, Chief Executive Officer and Chairman of the
Board. "We believe that our addition to the index will create
awareness and accessibility for institutional investors, increase
liquidity, and is recognition of our corporate achievements over
the last year."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $8.4 trillion in assets are benchmarked against
Russell's U.S. indexes. Russell indexes are part of FTSE Russell, a
leading global index provider.
For more information on the Russell Microcap Index and the
Russell indexes reconstitution, please visit the FTSE Russell
website.
About FTSE Russell
FTSE Russell is a leading global index provider creating and
managing a wide range of indexes, data and analytic solutions to
meet client needs across asset classes, style and strategies.
Covering 98% of the investable market, FTSE Russell indexes offer a
true picture of global markets, combined with the specialist
knowledge gained from developing local benchmarks around the
world.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$12.5 trillion is currently
benchmarked to FTSE Russell indexes. For over 30 years, leading
asset owners, asset managers, ETF providers and investment banks
have chosen FTSE Russell indexes to benchmark their investment
performance and create investment funds, ETFs, structured products
and index-based derivatives. FTSE Russell indexes also provide
clients with tools for asset allocation, investment strategy
analysis and risk management.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing
the IOSCO Principles. FTSE Russell is wholly owned by London Stock
Exchange Group.
For more information, visit www.ftserussell.com
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of technology to treat obesity
and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by
an FDA-approved pacemaker-like device called the vBloc® System, is
designed to help patients feel full and eat less by intermittently
blocking hunger signals on the vagus nerve. EnteroMedics recently
acquired the Gastric Vest System™ through its acquisition of
BarioSurg, Inc. The Gastric Vest is an investigational, minimally
invasive, laparoscopically implanted medical device being studied
for weight loss in morbidly obese patients. The device wraps around
the stomach, emulating the effect of conventional weight-loss
surgery, and enables gastric volume reduction without permanently
changing patient anatomy.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements generally can be identified
by the use of words such as "expect," "plan," "anticipate,"
"could," "may," "intend," "will," "continue," "future," other words
of similar meaning and the use of future dates. These
forward-looking statements are based on the current expectations of
our management and involve known and unknown risks and
uncertainties that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Applicable risks and uncertainties
related to the acquisition include, but are not limited to, the
following: the acquisition may involve unexpected costs or
liabilities; the ability to recognize benefits of the acquisition;
and risks that the merger disrupts current plans and operations.
Additional risks and uncertainties include, among others: our
limited history of operations; our losses since inception and for
the foreseeable future; our limited commercial sales experience
with our vBloc® System for the treatment of obesity in the United States or in any foreign market
other than Australia and the
European Community; the competitive industry in which we operate;
our ability to maintain compliance with the Nasdaq continued
listing requirements; our ability to commercialize our vBloc®
System; our dependence on third parties to initiate and perform our
clinical trials; the need to obtain regulatory approval for any
modifications to our vBloc® System; physician adoption of our
vBloc® System and vBloc® Neurometabolic Therapy; our
ability to obtain third party coding, coverage or payment levels;
ongoing regulatory compliance; our dependence on third party
manufacturers and suppliers; the successful development of our
sales and marketing capabilities; our ability to raise additional
capital when needed; international commercialization and operation;
our ability to attract and retain management and other personnel
and to manage our growth effectively; potential product liability
claims; the cost and management time of operating a public company;
potential healthcare fraud and abuse claims; healthcare legislative
reform; and our ability to obtain and maintain intellectual
property protection for our technology and products. These and
additional risks and uncertainties are described more fully in the
Company's filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in the
annual report on Form 10-K filed March 8,
2017 and quarterly report on Form 10-Q filed May 15, 2017. We are providing this information
as of the date of this press release and do not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/enteromedics-added-to-russell-microcap-index-300479074.html
SOURCE EnteroMedics Inc.